Jaime L. Chase

Partner
Full contact info

I enjoy utilizing my prior experience as an in-house lawyer and CPA to assist companies as they evolve from private to public.

Passions

Wine

New England Patriots

Travel

Experience

IN8bio – $40 Million IPO

August 4, 2021

Cooley advised IN8Bio on its $40 million initial public offering of 4,000,000 shares of common stock. IN8Bio, whose securities now trade on the Nasdaq Global Market under the symbol INAB, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell therapies. Partners Josh Kaufman, Jaime Chase and Josh Rottner led the Cooley team.

Related contacts

Josh Kaufman
Partner, New York
Jaime L. Chase
Partner, Washington, DC
Joshua Rottner
Partner, Boston

Related Practices & Industries

Sprinklr – $293 Million IPO

June 26, 2021

Cooley advised Sprinklr on its $292.6 million initial public offering of 18,287,500 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Sprinklr, whose securities now trade on the New York Stock Exchange under the symbol CXM, is the unified customer experience management platform for modern enterprises. Partners Nicole Brookshire, Josh Kaufman and Jaime Chase led the Cooley team.

Related contacts

Josh Kaufman
Partner, New York
Jaime L. Chase
Partner, Washington, DC
Charles York
Associate, New York

Related Practices & Industries

Five Prime Therapeutics Agrees to Sell to Amgen for $1.9 Billion

April 27, 2021

Cooley advised Five Prime Therapeutics, a publicly traded clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, on its agreement to sell to Amgen in an all-cash transaction with an equity value of approximately $1.9 billion. Partners Jamie Leigh, Ian Nussbaum and Laura Berezin led the Cooley team advising Five Prime.

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
Laura Berezin
Partner, Seattle
Jaime L. Chase
Partner, Washington, DC
Polina A. Demina
Associate, New York
Wendy Brenner
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Howard Morse
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Barbara Mirza
Partner, Los Angeles Santa Monica

Related Practices & Industries

IonQ Agrees to SPAC Merger With dMY Technology Group III

March 19, 2021

Cooley advised IonQ, a quantum computing hardware and software company, on its merger agreement with special purpose acquisition company dMY Technology Group III. Resulting in $650 million in gross proceeds, including $350 million from a fully committed PIPE, the transaction will make IonQ the first publicly traded pure-play hardware and software company in the quantum computing space. Partners Adam Ruttenberg, John McKenna, David Silverman, Jaime Chase and Mike Lincoln led the Cooley team advising IonQ.

Read more

Related contacts

Adam Ruttenberg
Partner, Washington, DC
John McKenna
Partner, Palo Alto
David Silverman
Partner, New York
Jaime L. Chase
Partner, Washington, DC
Mike Lincoln
Vice Chair, Reston
Alex Weaver
Associate, Washington, DC
Charles York
Associate, New York
Rasha Printz
Associate, Reston
Jacqueline Grise
Partner, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Tiana Demas
Partner
Eileen Marshall
Partner, Washington, DC
Rick Jantz
Associate, Los Angeles Santa Monica
Helenanne Connolly
Partner, Reston
Sharon Connaughton
Special Counsel, Washington, DC
Howard Morse
Partner, Washington, DC
David Walsh
Partner, Reston
Mary Maher Lewis
Special Counsel, Reston
Kevin King
Partner, Washington, DC
Sarah Oliai
Associate, Washington, DC
Dillon Martinson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Matthew D. Silverman
Special Counsel, San Diego

Related Practices & Industries

Ovid - $75 Million IPO

December 1, 2020

Cooley advised Ovid on its $75 million initial public offering of 5,000,000 shares of common stock. Ovid, which now trades on The NASDAQ Global Select Market as “OVID,” is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

Read more

Related contacts

Laura Berezin
Partner, Seattle
Div Gupta
Partner, New York
Jaime L. Chase
Partner, Washington, DC
Sara Semnani
Partner, Los Angeles Santa Monica
Jeramie Perez
Senior Paralegal, Palo Alto
Jason Minio
Paralegal Specialist, Boston
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Ivor Elrifi
Partner, New York
Heidi A. Erlacher
Partner, Boston
David Walsh
Partner, Reston
Mary Maher Lewis
Special Counsel, Reston
Francis Wheeler
Partner, Colorado

Related Practices & Industries

View more